Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 8, 2015; 7(10): 1297-1301
Published online Jun 8, 2015. doi: 10.4254/wjh.v7.i10.1297
Published online Jun 8, 2015. doi: 10.4254/wjh.v7.i10.1297
Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets
Fátima Higuera-de la Tijera, Liver Clinic, Gastroenterology Department, Mexico’s General Hospital “Dr. Eduardo Liceaga”, Mexico City 06726, Mexico
Alfredo I Servín-Caamaño, Diabetes, Obesity and Metabolic Syndrome Clinic, Internal Medicine Department, Mexico’s General Hospital “Dr. Eduardo Liceaga”, Mexico City 06726, Mexico
Author contributions: Higuera-de la Tijera F prepared and wrote the editorial; Servín-Caamaño AI made corrections and carried out final editing of the manuscript.
Conflict-of-interest: The authors involved in this manuscript (Fátima Higuera-de la Tijera, Alfredo I Servín-Caamaño) have no conflicting commercial, personal, political, intellectual, or religious interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Fátima Higuera-de la Tijera, MD, MSc, Liver Clinic, Gastroenterology Department, Mexico’s General Hospital “Dr. Eduardo Liceaga”, Eje 2A Sur (Dr. Balmis) 148, Cuauhtémoc, Doctores, Mexico City 06726, Mexico. fatimahiguera@yahoo.com.mx
Telephone: +52-55-27892000
Received: January 14, 2015
Peer-review started: January 18, 2015
First decision: February 7, 2015
Revised: February 21, 2015
Accepted: March 16, 2015
Article in press: March 18, 2015
Published online: June 8, 2015
Peer-review started: January 18, 2015
First decision: February 7, 2015
Revised: February 21, 2015
Accepted: March 16, 2015
Article in press: March 18, 2015
Published online: June 8, 2015
Core Tip
Core tip: Non-alcoholic fatty liver disease (NAFLD) is an important health care problem. The pathophysiology of NAFLD and non-alcoholic steatohepatitis (NASH) and their progression are multifactorial and complex processes, where multi-parallel simultaneous hits derived from the gut and adipose tissue promote a pro-inflammatory response and liver injury. All of these represent attractive therapeutic targets. Pharmacological agents such as glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, ursodeoxycholic acid, obeticholic acid and probiotics need to be explored in clinical trials specifically for treating NAFLD and NASH.